在皮肤病学中怀孕和哺乳期间的生物使用:基于证据的审查
Journal of drugs in dermatology : JDD
|November 4, 2024
概括
生物药物为怀孕期间皮肤病的治疗提供了至关重要的治疗方法. 本综述总结了它们的安全性,指导从怀孕前到产后的使用,以获得更好的孕产妇和胎儿结果.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 生物药物已经改变了皮肤护理,但在怀孕和母乳养期间引发了安全问题.
- 炎症性皮肤疾病在怀孕期间可能是不可预测的,需要有效的治疗.
- 关于生物制剂在孕妇和哺乳期人群中的安全性数据有限.
研究的目的:
- 综合审查常用的皮肤生物学药物的妊娠安全性.
- 提供基于证据的建议,用于在怀孕前,怀孕和分娩后的生物使用.
- 为了检查与生物药物相关的生育能力,胎盘移植和产后免疫调节.
主要方法:
- 对孕妇和哺乳期生物使用研究的系统文献综述.
- 对胎盘转移和对新生儿的影响数据的分析.
- 评估生育能力和产后免疫反应.
主要成果:
- 生物药物可以在怀孕期间管理皮肤病的关键.
- 关于胎盘转移和新生儿后果的数据在不同的生物药物中各不相同.
- 为优化整个妊娠连续性的生物治疗提供了建议.
结论:
- 生物药物可以安全地考虑用于孕妇和哺乳期患者的皮肤病症管理.
- 个性化风险-益处评估对于指导生物治疗至关重要.
- 需要进一步的研究,以充分阐明长期安全性.
相关概念视频
Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Development of Human Microbiota
The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
Development of the Oral Microbiota
The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...


